Ultomiris (ravulizumab) was shown to efficiently manage atypical hemolytic uremic syndrome (aHUS) in a woman in her 30s…
Articles by Vanda Pinto, PhD
COVID-19 might have triggered a relapse of atypical hemolytic uremic syndrome (aHUS) in a 36-year-old woman, according to a…
An 11-year-old boy with atypical hemolytic uremic syndrome (aHUS) became severely ill following infection with SARS-CoV-2, the virus that…
A newly identified mutation in the TSEN2 gene that causes craniofacial abnormalities, intellectual and developmental disabilities, as well as…
By shortening the time spent on treatment, Ultomiris (ravulizumab), an approved therapy for atypical hemolytic uremic syndrome (aHUS),…
If closely monitored, women with atypical hemolytic uremic syndrome (aHUS) can have successful and uncomplicated pregnancies, including those on…
COVID-19 appears to have triggered an exaggerated immune response in a toddler, leading to the development of atypical hemolytic…
The case of a woman with unusual symptoms for atypical hemolytic uremic syndrome (aHUS) — including normal hemoglobin levels…